Piper Jaffray analyst Christopher Raymond reiterated an Overweight rating and $22.00 price target on Akebia Therapeutics (NASDAQ: AKBA) after performing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE